Table 1.
Clinical characteristics and treatment outcomes of patients with extranodal nasal-type NK/T-cell lymphoma.
| Patients | 5-year OS rate post-treatment | SMR | |||
|---|---|---|---|---|---|
| Characteristics | No. (%) | % (95% CI) | P | (95% CI) | Pa |
| Sex | 0.181 | ||||
| Male | 1261 (70.4) | 71.7 (68.9–74.6) | 5.6 (5.1–6.3) | <0.001 | |
| Female | 529 (29.6) | 74.5 (70.4–78.7) | 1.3 (1.1–1.5) | <0.001 | |
| Age (years) | 0.013 | ||||
| ≤60 | 1527 (85.3) | 73.5 (71.1–76.0) | 14.7 (13.2–16.3) | <0.001 | |
| >60 | 263 (14.7) | 66.4 (59.9–73.6) | 1.9 (1.5–2.3) | <0.001 | |
| Primary site | <0.001 | ||||
| UADT | 716 (40.0) | 73.9 (71.6–76.3) | 6.3 (5.7–7.0) | <0.001 | |
| Extra-UADT | 1074 (60.0) | 45.4 (34.0–60.8) | 14.3 (10.6–19.3) | <0.001 | |
| Regional lymph nodes | <0.001 | ||||
| Yes | 1674 (93.5) | 64.7 (60.9–68.8) | 13.3 (11.6–15.2) | <0.001 | |
| No | 116 (6.5) | 77.4 (74.6–80.3) | 4.5 (3.9––5.1) | <0.001 | |
| Distant lymph nodes | <0.001 | ||||
| Yes | 1671 (93.4) | 46.3 (35.7–60.2) | 17.8 (13.2–24.2) | <0.001 | |
| No | 119 (5.6) | 73.8 (71.5–76.2) | 6.2 (5.7–6.9) | <0.001 | |
| Primary tumor invasion | <0.001 | ||||
| Yes | 1004 (56.1) | 67.9 (64.8–71.2) | 9.7 (8.6–10.8) | <0.001 | |
| No | 786 (43.9) | 78.4 (75.1–81.8) | 4.1 (3.5–4.8) | <0.001 | |
| B symptoms | 0.006 | ||||
| Yes | 687 (38.4) | 68.9 (65.2–72.9) | 9.9 (8.6–11.5) | <0.001 | |
| No | 1103 (61.6) | 74.8 (71.9–77.8) | 5.3 (4.6–6.0) | <0.001 | |
| Elevated LDH | <0.001 | ||||
| Yes | 100 (5.6) | 60.1 (55.3–65.3) | 1.2 (1.1–1.4) | <0.001 | |
| No | 1690 (94.4) | 77.1 (74.5–79.7) | 5.1 (4.5–5.8) | <0.001 | |
| ECOG score | <0.001 | ||||
| 0–1 | 1563 (87.3) | 74.7 (72.4–77.1) | 6.2 (5.6–6.8) | <0.001 | |
| ≥2 | 227 (12.7) | 39.1 (30.2–50.7) | 12.9 (10.1–16.5) | <0.001 | |
| Ann Arbor stage | <0.001 | ||||
| I-II | 1296 (72.4) | 75.9 (73.5–78.3) | 5.5 (5.0–6.1) | <0.001 | |
| III-IV | 494 (27.6) | 44.4 (36.7–53.7) | 24.4 (19.9–29.8) | <0.001 | |
| KPI | <0.001 | ||||
| Group 1 | 550 (30.7) | 81.8 (78.3–85.5) | 3.1 (2.5–3.8) | <0.001 | |
| Group 2 | 636 (35.5) | 75.0 (71.2–79.0) | 6.2 (5.2–7.3) | <0.001 | |
| Group 3 | 373 (20.9) | 67.4 (62.4–72.9) | 10.6 (8.7–12.8) | <0.001 | |
| Group 4 | 231 (12.9) | 49.6 (42.6–57.9) | 27.9 (22.9–34.1) | <0.001 | |
| PINK | <0.001 | ||||
| Low risk | 1269 (70.9) | 78.1 (75.6–80.6) | 11.4 (10.1–12.9) | <0.001 | |
| Intermediate risk | 363 (20.3) | 61.7 (55.9–68.1) | 3.1 (2.6–3.7) | <0.001 | |
| High risk | 158 (8.8) | 45.5 (36.6–56.6) | 12.8 (10.0–16.3) | <0.001 | |
| NRI | <0.001 | ||||
| Low risk | 390 (21.8) | 86.4 (82.6–90.3) | 5.6 (4.2–7.4) | <0.001 | |
| Intermediate-low risk | 517 (28.9) | 78.3 (74.3–82.5) | 3.9 (3.2–4.8) | <0.001 | |
| Intermediate-high risk | 469 (26.2) | 69.8 (65.3–74.8) | 7.0 (5.9–8.4) | <0.001 | |
| High risk | 263 (14.7) | 59.4 (52.9–66.6) | 11.0 (8.9–13.6) | <0.001 | |
| Very high risk | 151 (8.4) | 43.2 (24.8–53.7) | 12.2 (9.7–15.3) | <0.001 | |
OS overall survival, SMR standardized mortality ratio, CI confidence interval, UADT upper aerodigestive tract, LDH lactate dehydrogenase, ECOG Eastern Cooperative Oncology Group, KPI Korean Prognostic Index, PINK Prognostic Index of Natural Killer Lymphoma, NRI nomogram-revised risk index.
aCompared with the age- and sex-matched general Chinese population.